Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial.

ABSTRACT:

Introduction

Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but it is markedly underutilized, particularly in the US Black population, partly because of concern over clozapine-associated low absolute neutrophil count (ANC). People of African descent have a lower normative ANC range than the White population, which is associated with a specific "ACKR1-null" ("Duffy null") CC genotype (SNP rs2814778) on the ACKR1 gene, termed benign ethnic neutropenia (BEN). The range of ANC variability and safety of clozapine have not been established in people with BEN or examined prospectively in people of African descent.

Methods

We completed a multisite, 6-month, prospective, open-label clinical trial of clozapine treatment in people of African descen

SUBMITTER: Kelly DL 

PROVIDER: S-EPMC10891303 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature